News Aldeyra’s reproxalap for dry eye disease accepted by FDA Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New D
News Aldeyra spies FDA filing ahead for dry eye drug reproxalap Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off.
News Aldeyra builds case for troubled dry eye drug reproxalap Prospects for Aldeyra's dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn't giving up and h
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
